Attenuated vesicular stomatitis viruses as vaccine vectors
about
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primatesVesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesEffective post-exposure treatment of Ebola infectionDevelopment of a new vaccine for the prevention of Lassa fever.Phase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeN-terminal domain of Borna disease virus G (p56) protein is sufficient for virus receptor recognition and cell entryCharacterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins.Evaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine VehicleChikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the BrainEbola hemorrhagic Fever and the current state of vaccine developmentVesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.Analysis of hemagglutinin-mediated entry tropism of H5N1 avian influenza.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion.Viral vector-based influenza vaccines.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesModel-based design of growth-attenuated virusesRefined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodiesA cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression.Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.Recombinant Newcastle disease virus as a vaccine vectorPeri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine.Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primatesVirus-vectored influenza virus vaccines.A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animalsStimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin.High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteinsIntranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced diseaseA single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challengeSecond-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic
P2860
Q21090120-3088FACE-B618-42A9-8A14-BDA56F74697AQ21131585-053FF74D-E60E-414A-BE4D-FB6375D119C6Q21131616-0DB13D68-B5CE-49DB-A170-08582DF5B12EQ21563440-7ACB613B-8117-4045-9719-40042E99EB10Q24289281-CCAF2EDD-D656-438B-B186-20B0BFA4EB23Q24529164-713AFA5B-2819-486B-9F87-E22FBBE3721EQ27472885-2228BEAA-0466-4E9C-9C12-26506D3738ECQ27473287-3C5C352B-F206-454E-A2F1-F536795B22F7Q28223031-C262584E-7A26-4F00-B57B-CB9C5E17D280Q30205198-22DC2DF2-B445-48AB-9DE4-51E7E7BD1A3DQ30361939-566B80A1-A89F-41FA-B4C5-B1C657EEF551Q30370147-5CFFAEDC-D374-4B34-A689-FFA80BEB9AF9Q30375938-D6986B2E-43B5-4F70-B8F9-AE4B2E57A699Q30382097-D7B0B8DA-8392-4CBD-A546-9FD704B9F494Q30385999-52F16232-CC27-45E5-8688-4A369BBDFB3BQ30389455-EBFE6088-D7DB-4E19-B245-90CCA370AB23Q30390938-DD2D3E23-CEBF-4AA0-AD87-4820D1260790Q30427591-B7C2B276-E556-4AC5-9AA5-21E468D4D0E5Q33256104-09FF6ECB-64C8-4EC5-975C-D81A96C12CF1Q33721746-F3D1525F-8D90-4790-99C1-1D73A9B113CCQ33725635-AFF3403D-DBC4-4041-95A6-F77A3081D040Q33743852-2D5A77E5-25C4-40B3-A6EF-3E3D947FFE61Q33804540-2C3DA0EA-38BC-4CB0-B9D5-7164897F223AQ33808044-7C5314B5-2DBB-4549-820A-2BD3ED09AD38Q33826382-0DD3CA34-B9AB-4FB4-98F7-D49CA6F841F0Q33849224-E6E03714-9CCF-44F1-88FE-32862BA2FA2BQ33850246-B7038647-551B-4A4E-AF74-8C3D2B6541F7Q33894405-D0E502BC-96B4-4E66-BE05-9ED86C5E8818Q34013572-0C59C4E0-DF99-4D57-A42A-5FE7511D50A1Q34092753-61818B2D-F1DD-448D-A5FC-D9D71DA1713BQ34092801-92B49CAE-72DE-475B-BA78-B9EB92F7B3BFQ34102268-5C884725-1167-4F79-9094-D4DB3714603EQ34172295-CC2A9CE4-CF7F-42AA-A43E-09FF139D4F2FQ34228558-A96F1769-C843-41A8-BACF-106FDD1281A7Q34296055-D3D35C6C-6C8F-4647-8D8E-C070B65EF62BQ34333167-DA3FD375-95D4-4241-8CD8-94759CCD6E37Q34343020-9569DA98-AA97-4CE2-8E89-F23F021A2ABEQ34344372-F228EF0B-A549-496B-ADA8-33A104EF6597Q34434713-D0841067-37E8-49AB-BA65-85763D5302E8Q34461764-D3D19C95-9882-4791-A615-987AB1B84035
P2860
Attenuated vesicular stomatitis viruses as vaccine vectors
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Attenuated vesicular stomatitis viruses as vaccine vectors
@ast
Attenuated vesicular stomatitis viruses as vaccine vectors
@en
Attenuated vesicular stomatitis viruses as vaccine vectors
@nl
type
label
Attenuated vesicular stomatitis viruses as vaccine vectors
@ast
Attenuated vesicular stomatitis viruses as vaccine vectors
@en
Attenuated vesicular stomatitis viruses as vaccine vectors
@nl
prefLabel
Attenuated vesicular stomatitis viruses as vaccine vectors
@ast
Attenuated vesicular stomatitis viruses as vaccine vectors
@en
Attenuated vesicular stomatitis viruses as vaccine vectors
@nl
P2093
P2860
P921
P3181
P1433
P1476
Attenuated vesicular stomatitis viruses as vaccine vectors
@en
P2093
P2860
P304
P3181
P577
1999-05-01T00:00:00Z